Cancer Therapy News and Research

RSS

Researchers examine how terpenes can inhibit growth of liver cancer cells

As main component of essential oils, terpenes can inhibit the growth of different cancer cells. Researchers from the Ruhr-University Bochum headed by Prof Dr Dr Dr Hanns Hatt have analysed this process in liver cancer cells in detail.

19 Jan 2015

MD Anderson honored with top science and technology award in China

The University of Texas MD Anderson Cancer Center was presented the People's Republic of China International Science and Technology Cooperation Award at a ceremony held Jan. 9 at Beijing's Great Hall of the People.

16 Jan 2015

GenSpera reports encouraging results from mipsagargin Phase II study for HCC treatment

GenSpera Inc. today announced the encouraging results of a Phase II study of mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC).

16 Jan 2015

Philips, Indica Labs partner to offer advanced image analysis algorithms for cancer research

Royal Philips today announced that it will further support oncology researchers' efforts to analyze pathology samples by offering advanced image analysis algorithms from Indica Labs, Inc. as part of its Digital Pathology Solutions offerings.

15 Jan 2015

Sophia Genetics obtains CE-IVD marking for BRCA1/2 testing solution

Sophia Genetics, the European leader in Data Driven Medicine, has today obtained CE-IVD marking for its solution to detect BRCA1/2 associated genetic variants in live tumours.

14 Jan 2015

Intrexon and ZIOPHARM Oncology sign exclusive licensing agreement with MD Anderson

Intrexon Corporation, a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology, today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.

14 Jan 2015

HLI gains access to PGDx's cancer genomics solutions to expand cancer genome analysis

Personal Genome Diagnostics, Inc., a provider of advanced cancer genome analysis and testing services, and Human Longevity, Inc., the human health information technology and health care company, today announced that HLI will have access to PGDx's cancer genomics solutions to expand its analysis of cancer genomes, including CancerSelect, PlasmaSelect, CancerXome, METDetect and CancerComplete.

12 Jan 2015

QIAGEN's circulating tumor DNA test CE-IVD marked to assess genomic mutation NSCLC patients

QIAGEN announced today the CE-IVD marking of its novel liquid biopsy-based companion diagnostic that analyzes circulating nucleic acids obtained from blood samples to assess an important genomic mutation in patients with non-small cell lung cancer (NSCLC), the most common form of this cancer.

From QIAGEN Manchester Limited 12 Jan 2015

Research findings may lead to new therapeutic target for AML treatment

A study by the Cancer Science Institute of Singapore at the National University of Singapore has found new interactions between two molecules involved in acute myeloid leukaemia (AML), STAT3 and PRL-3, which may offer a new therapeutic target for cancer treatment.

12 Jan 2015

U-M researchers reveal key gene that may provide potential target for cancer treatment

One of the mysteries in cancer biology is how one protein, TGF-beta, can both stop cancer from forming and encourage its aggressive growth.

6 Jan 2015

Brazilian researchers find that nutrition education may help prevent reoccurrence of breast cancer

Breast cancer is the most frequent cause of death among women worldwide, and five-year survival rates are just 58.4% in Brazil, lower than in many other regions. In a new study, however, researchers from Federal University of Santa Catarina provided Brazilian breast cancer patients with nutrition education and found it could benefit patients and may help prevent reoccurrence of the cancer.

6 Jan 2015

Holding breath during radiation therapy can reduce radiation exposure to the heart

Women who have breast cancer on their left side present a particular challenge to radiation oncologists. Studies have shown that the risk of heart disease is higher in this group of women after radiation treatment because it can be difficult to ensure that a sufficient dose of radiation is delivered to the left breast while adequately shielding the heart from exposure.

5 Jan 2015

UT Southwestern researchers target cells' biological clock to kill cancer cells, shrink tumor growth

Cell biologists at UT Southwestern Medical Center have targeted telomeres with a small molecule called 6-thiodG that takes advantage of the cell's 'biological clock' to kill cancer cells and shrink tumor growth.

2 Jan 2015

New treatment approach may improve survival rates for certain patients with stage 4 lung cancer

A clinical trial that combined stereotactic body radiation therapy with a specific chemotherapy regimen more than doubled survival rates for certain stage 4 lung cancer patients, UT Southwestern Medical Center cancer researchers report.

2 Jan 2015

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014.

1 Jan 2015

New therapeutic approach shows potential for treating cancer

Case Western Reserve researchers have identified a two-pronged therapeutic approach that shows great potential for weakening and then defeating cancer cells.

31 Dec 2014

UTSA, UTHSCSA researchers to jointly develop next-generation breast cancer treatment drugs

Stanton McHardy, associate professor of chemistry and director of the Center for Innovative Drug Discovery in The University of Texas at San Antonio College of Sciences, is partnering on a $1.9 million award to develop next-generation breast cancer treatment drugs.

19 Dec 2014

Certain complementary medicines may cause side effects, warns NPS MedicineWise

With new information from Melbourne’s Peter MacCallum Cancer Centre revealing that some complementary medicines can interact with cancer treatment, NPS MedicineWise reminds all Australians that complementary medicines can cause side effects, and interact with other over-the-counter and prescription medicines.

19 Dec 2014

Elekta's Flexitron brachytherapy afterloading platform approved in China

Elekta announces that the China Food and Drug Administration has approved Elekta's Flexitron brachytherapy afterloading platform for sale and marketing in China.

From Elekta 18 Dec 2014

Sugar-based molecular microcapsule eliminates toxicity of anticancer agent

Johns Hopkins researchers have developed a sugar-based molecular microcapsule that eliminates the toxicity of an anticancer agent developed a decade ago at Johns Hopkins, called 3-bromopyruvate, or 3BrPA, in studies of mice with implants of human pancreatic cancer tissue. The encapsulated drug packed a potent anticancer punch, stopping the progression of tumors in the mice, but without the usual toxic effects.

18 Dec 2014